Suppr超能文献

目前治疗远端获得性泪道阻塞的最佳方法:系统评价和荟萃分析。

Best treatments available for distal acquired lacrimal obstruction: A systematic review and meta-analysis.

机构信息

Division of Head and Neck department, Otorhinolaryngology unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.

CUSSB, University Centre for Statistics in the Biomedical Sciences, San Raffaele Hospital, Vita-Salute University, Milano, Italy.

出版信息

Clin Otolaryngol. 2020 Jul;45(4):545-557. doi: 10.1111/coa.13551. Epub 2020 May 6.

Abstract

BACKGROUND

Epiphora is a common clinical sign whose primary cause is post-canalicular lacrimal obstruction. Treatment is both surgical and non-surgical. In the literature, there is some evidence to suggest that some treatments are superior to others, but there are no direct comparative data in this regard.

OBJECTIVE OF REVIEW

To analyse the success rates of all available treatments to resolve post-canalicular acquired lacrimal obstruction.

TYPE OF REVIEW

Systematic review and meta-analysis.

SEARCH STRATEGY

A literature search was conducted in the US National Library of Medicine (PubMed), EMBASE, SCOPUS and Cochrane databases with a final search performed in January 2020.

EVALUATION METHOD

The search strategy identified articles published later than 2000 with at least 50 procedures performed both surgically (external dacryocystorhinostomy [EXT-DCR], endoscopic dacryocystorhinostomy [END-DCR] and transcanalicular laser dacryocystorhinostomy [TCL-DCR]) and non-surgically (balloon dacryoplasty [DCP], probing-stenting [SP] and polyurethane stent [PoS]). The primary outcome was functional success, defined as symptom resolution or less than MUNK 2 scale; in addition to this, the influence of adjunctive treatments, such as application of mitomycin C and post-procedural silicone stenting, was evaluated.

RESULTS

In total, 14 958 papers were selected, 440 of which were reviewed after screening; 55 were included after full-text review, which involved 9337 procedures. Mean success rate was 48.9% (35.7%-62.3%) for DCP, 54.4% (41.8%-66.5%) for SP, 73.6% (59.7%-84%) for PoS, 80% (75.1%-84%) for TCL-DCR, 89.8% (83.3%-93.9%) for EXT-DCR and 89.5% (87.2%-91.5%) for END-DCR. Among all procedures, a difference was noted between DCP and END-DCR (P < .001), DCP and EXT-DCR (P < .001), SP and END-DCR (P < .001), SP and EXT-DCR (P < .001), END-DCR and PoS (P = .016), and END-DCR and TCL-DCR (P = .001); no differences were noted between END-DCR and EXT-DCR (P = 1.00), EXT-DCR and PoS (P = .121) and EXT-DCR and TCL-DCR (P = .223). Considering surgical procedures, no differences were seen if a silicone stenting was applied, whereas, due to heterogeneity of the literature data, no statistical analysis was feasible for application of mitomycin C.

CONCLUSIONS

Our analyses suggest that, among all procedures available, END-DCR and EXT-DCR should be considered as treatments of choice to resolve distal acquired lacrimal obstruction.

摘要

背景

溢泪是一种常见的临床征象,其主要原因是泪道后端阻塞。治疗方法包括手术和非手术。文献中,有一些证据表明某些治疗方法优于其他方法,但在这方面没有直接的比较数据。

目的

分析所有可用的治疗方法以解决后天性泪道阻塞的成功率。

类型的审查

系统评价和荟萃分析。

搜索策略

在美国国立医学图书馆(PubMed)、EMBASE、SCOPUS 和 Cochrane 数据库中进行文献检索,并于 2020 年 1 月进行了最终检索。

评估方法

搜索策略确定了发表时间晚于 2000 年的文章,至少有 50 例手术(外部泪囊鼻腔吻合术[EXT-DCR]、内镜下泪囊鼻腔吻合术[END-DCR]和经泪小管激光泪囊鼻腔吻合术[TCL-DCR])和非手术(球囊扩张术[DCP]、探通置管术[SP]和聚氨酯支架[PoS])的治疗方法。主要结局为功能性成功,定义为症状缓解或 MUNK 2 量表评分低于 2 分;此外,还评估了辅助治疗(如丝裂霉素 C 的应用和术后硅胶支架)的影响。

结果

共筛选出 14958 篇论文,其中 440 篇经筛选后进行了回顾,55 篇经全文回顾后纳入,共涉及 9337 例手术。DCP 的平均成功率为 48.9%(35.7%-62.3%),SP 为 54.4%(41.8%-66.5%),PoS 为 73.6%(59.7%-84%),TCL-DCR 为 80%(75.1%-84%),EXT-DCR 为 89.8%(83.3%-93.9%),END-DCR 为 89.5%(87.2%-91.5%)。在所有手术中,DCP 与 END-DCR(P<0.001)、DCP 与 EXT-DCR(P<0.001)、SP 与 END-DCR(P<0.001)、SP 与 EXT-DCR(P<0.001)、END-DCR 与 PoS(P=0.016)和 END-DCR 与 TCL-DCR(P=0.001)之间存在差异;但 END-DCR 与 EXT-DCR(P=1.00)、EXT-DCR 与 PoS(P=0.121)和 EXT-DCR 与 TCL-DCR(P=0.223)之间无差异。考虑到手术治疗,应用硅胶支架并没有差异,但由于文献数据的异质性,无法对丝裂霉素 C 的应用进行统计学分析。

结论

我们的分析表明,在所有可用的治疗方法中,END-DCR 和 EXT-DCR 应被视为解决远端后天性泪道阻塞的首选治疗方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验